Aug 10 (Reuters) - Gilead Sciences Inc said on Monday it has filed a marketing application with the U.S. Food and Drug Administration for its experimental COVID-19 drug remdesivir. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Sriraj Kalluvila)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.46 USD | -0.50% | -1.71% | -20.00% |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
05-01 | Deutsche Bank Adjusts Price Target on Gilead Sciences to $73 From $75 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.00% | 80.78B | |
+28.50% | 662B | |
+22.23% | 546B | |
-4.93% | 359B | |
+16.97% | 323B | |
+4.08% | 289B | |
+13.68% | 234B | |
+3.84% | 198B | |
-10.35% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences : files U.S. marketing application for remdesivir